Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?
作者信息
Kim Dong Yun, Park Jun Yong
机构信息
Department of Pharmacology, Yonsei University Graduate School of Medicine, Seoul, South Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
出版信息
Hepatobiliary Surg Nutr. 2019 Oct;8(5):522-524. doi: 10.21037/hbsn.2019.05.08.
Abstract
摘要
相似文献
1
Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?非酒精性脂肪性肝病新兴治疗方法概述：需要不止一种药物吗？
Hepatobiliary Surg Nutr. 2019 Oct;8(5):522-524. doi: 10.21037/hbsn.2019.05.08.
2
Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病的当前和新兴疗法。
Drugs. 2019 Jan;79(1):75-84. doi: 10.1007/s40265-018-1040-1.
3
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.他汀类药物治疗非酒精性脂肪性肝病的疗效及安全性。
Dig Liver Dis. 2015 Jan;47(1):4-11. doi: 10.1016/j.dld.2014.07.170. Epub 2014 Sep 16.
4
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.关注用于治疗非酒精性脂肪性肝病患者的新兴药物。
World J Gastroenterol. 2014 Dec 7;20(45):16841-57. doi: 10.3748/wjg.v20.i45.16841.
5
[Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].[非酒精性脂肪性肝病作为代谢综合征的一个组成部分及其与其他肝外疾病的因果关系]
Orv Hetil. 2017 Dec;158(52):2051-2061. doi: 10.1556/650.2017.30936.
6
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病
BMC Med. 2017 Feb 28;15(1):45. doi: 10.1186/s12916-017-0806-8.
7
Review article: the metabolic syndrome and non-alcoholic fatty liver disease.综述文章：代谢综合征与非酒精性脂肪性肝病
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:31-6. doi: 10.1111/j.1365-2036.2005.02592.x.
8
Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.非酒精性脂肪性肝病患者的治疗：当前观点与展望
Dig Liver Dis. 2006 Nov;38(11):789-801. doi: 10.1016/j.dld.2006.04.009. Epub 2006 Jun 5.
9
Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis.同型半胱氨酸水平与经活检证实的非酒精性脂肪性肝病的关联：一项荟萃分析。
J Clin Biochem Nutr. 2016 Jan;58(1):76-83. doi: 10.3164/jcbn.15-54. Epub 2015 Aug 29.
10
A new risk factor for the development of non-alcoholic fatty liver disease: HLA complex genes.
Turk J Gastroenterol. 2011 Aug;22(4):395-9. doi: 10.4318/tjg.2011.0237.
引用本文的文献
1
Hepatoprotective effects of Xiaoyao San formula on hepatic steatosis and inflammation regulating the sex hormones metabolism.逍遥散配方对肝脂肪变性和炎症的保肝作用及对性激素代谢的调节作用。
World J Hepatol. 2024 Jul 27;16(7):1051-1066. doi: 10.4254/wjh.v16.i7.1051.
本文引用的文献
1
Serotonin signals through a gut-liver axis to regulate hepatic steatosis.血清素通过肠-肝轴传递信号以调节肝脂肪变性。
Nat Commun. 2018 Nov 16;9(1):4824. doi: 10.1038/s41467-018-07287-7.
2
FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury.FXR 抑制内质网应激诱导的肝细胞 NLRP3 炎性小体并改善肝损伤。
Cell Rep. 2018 Sep 11;24(11):2985-2999. doi: 10.1016/j.celrep.2018.07.068.
3
Recent research trends and updates on nonalcoholic fatty liver disease.非酒精性脂肪性肝病的最新研究趋势和进展。
Clin Mol Hepatol. 2019 Mar;25(1):1-11. doi: 10.3350/cmh.2018.0037. Epub 2018 Aug 8.
4
Mechanisms of NAFLD development and therapeutic strategies.非酒精性脂肪性肝病发病机制及治疗策略。
Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.
5
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.一项关于西尼利尤单抗治疗伴有纤维化的非酒精性脂肪性肝炎的随机、安慰剂对照试验。
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.
6
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.纤维化分期而非 NASH 可预测经活检证实的非酒精性脂肪性肝病患者的死亡率和严重肝脏疾病的发生时间。
J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027. Epub 2017 Aug 10.
7
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.依洛前列素，一种过氧化物酶体增殖物激活受体-α和-δ激动剂，可在不加重肝纤维化的情况下诱导非酒精性脂肪性肝炎消退。
Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.
8
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.基于前瞻性双胞胎研究的肝纤维化和脂肪变性的遗传性。
Gastroenterology. 2015 Dec;149(7):1784-93. doi: 10.1053/j.gastro.2015.08.011. Epub 2015 Aug 20.
9
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.肝纤维化而非其他组织学特征与非酒精性脂肪性肝病患者的长期预后相关。
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
10
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.纤维化分期是经过长达 33 年随访后，NAFLD 患者疾病特异性死亡率的最强预测因子。
Hepatology. 2015 May;61(5):1547-54. doi: 10.1002/hep.27368. Epub 2015 Mar 23.
Zotero 插件